Clinical-stage biopharmaceutical company Viking Therapeutics Inc (Viking) (NASDAQ: VKTX), which is focused on the development of novel therapies for metabolic and endocrine disorders, revealed on Wednesday that it has received positive results from its Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial of VK2735.
The company said that this compound is a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors in development for the potential treatment of various metabolic disorders.
It added that based on these Phase 1 results, it plans to initiate a Phase 2 study of VK2735 in patients with obesity in mid-2023.
Brian Lian, PhD, chief executive officer of Viking, stated: "These Phase 1 data highlight VK2735's attractive early profile, with encouraging safety, tolerability, and positive effects on body weight. The initial data suggest excellent clinical characteristics, with good tolerability and up to approximately 18 pounds of mean weight loss from baseline. Though subjects in this study were only exposed to higher doses for a limited time, no signs of plateau were observed. We look forward to exploring higher doses over a longer treatment window in the Phase 2 trial."
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients